News
For adults with type 2 diabetes and obesity, GLP-1 RAs are associated with a lower risk for dementia, stroke, and all-cause mortality.
(1276.HK; 600276.SH) delivered a piece of good news for investors with positive trial data for a dual-acting obesity drug ...
GLP-1 drugs for diabetes and weight loss are difficult for some people to inject weekly. A new slow-release gel, tested in rats, could help.
Positive topline results of the LunAIRo trial put AD109 on track for approval as the first oral sleep apnoea medication.
The analysis found that while the amount of weight regain varies by drug, there is a consistent pattern of rapid weight ...
Munich news, health insurance, technology, jobs and other topics for expatriates. The Eye Newspapers covers daily news and offers services for foreigners.
2d
Zacks Investment Research on MSNAmgen vs. Novo Nordisk: Which Pharma Giant Is the Better Buy?
Amgen AMGN and Novo Nordisk NVO are among the largest companies in the pharmaceutical space. Amgen boasts one of the largest ...
Tirzepatide was superior to semaglutide in achieving standard and intensive cardiometabolic targets among patients with type 2 diabetes.
Curious about the viral “Japanese Mounjaro” drink? Learn what it is, what it’s made of, and whether it can actually support ...
A new study has found that a diabetes medicine called tirzepatide can help people lower their blood sugar and lose weight ...
Tirzepatide outperformed semaglutide in simultaneously achieving four key therapeutic targets for type 2 diabetes.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results